[
  {
    "ts": null,
    "headline": "How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine",
    "summary": "Eli Lilly's plan to buy Ventyx for $1.2 billion benefits more than the takeover target, an analyst said Thursday.",
    "url": "https://finnhub.io/api/news?id=d69f1a12f06a5e112a03456e0485f6a40f79fa6d8fcb3b0143477921b1bd9ef4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767885214,
      "headline": "How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine",
      "id": 138036585,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's plan to buy Ventyx for $1.2 billion benefits more than the takeover target, an analyst said Thursday.",
      "url": "https://finnhub.io/api/news?id=d69f1a12f06a5e112a03456e0485f6a40f79fa6d8fcb3b0143477921b1bd9ef4"
    }
  },
  {
    "ts": null,
    "headline": "Is LLY's Ventyx Deal Another Attempt at Diversification Beyond GLP-1?",
    "summary": "Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space intensifies.",
    "url": "https://finnhub.io/api/news?id=fc555d45be77d8a0280bbabd09941d06dffb52cfac79ea0a7be742cce75e0877",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767882900,
      "headline": "Is LLY's Ventyx Deal Another Attempt at Diversification Beyond GLP-1?",
      "id": 138036586,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space intensifies.",
      "url": "https://finnhub.io/api/news?id=fc555d45be77d8a0280bbabd09941d06dffb52cfac79ea0a7be742cce75e0877"
    }
  },
  {
    "ts": null,
    "headline": "RVMD Stock Hits a Record High on Rumored Takeover Interest",
    "summary": "Revolution Medicines shares jump nearly 29% to a record high after a WSJ report said AbbVie showed takeover interest, a claim the pharma giant later denied.",
    "url": "https://finnhub.io/api/news?id=5996d2d4c5d9d92f7a59d3a3ed29abfc34279d5be0678fee5b8703faa547292d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767881460,
      "headline": "RVMD Stock Hits a Record High on Rumored Takeover Interest",
      "id": 138036587,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Revolution Medicines shares jump nearly 29% to a record high after a WSJ report said AbbVie showed takeover interest, a claim the pharma giant later denied.",
      "url": "https://finnhub.io/api/news?id=5996d2d4c5d9d92f7a59d3a3ed29abfc34279d5be0678fee5b8703faa547292d"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Large Cap Growth Strategy’s Thoughts on Eli Lilly and Company (LLY)",
    "summary": "ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth-quarter 2025 investor letter. The investment philosophy of the strategy is to invest in leading companies that are undervalued by the market in terms of their future growth potential. A copy of the letter can be downloaded here. Large-cap stocks continued their […]",
    "url": "https://finnhub.io/api/news?id=05b23d9cc154a5babddc5a3bf842ea203fdaa1ab6fe9ef27465002691f2ccccb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767878211,
      "headline": "ClearBridge Large Cap Growth Strategy’s Thoughts on Eli Lilly and Company (LLY)",
      "id": 138036588,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth-quarter 2025 investor letter. The investment philosophy of the strategy is to invest in leading companies that are undervalued by the market in terms of their future growth potential. A copy of the letter can be downloaded here. Large-cap stocks continued their […]",
      "url": "https://finnhub.io/api/news?id=05b23d9cc154a5babddc5a3bf842ea203fdaa1ab6fe9ef27465002691f2ccccb"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks' Dark Winter Is Over. What That Means For Investors.",
    "summary": "The long winter for biotech stocks is over.  Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, and a surprising, if uneasy, alliance with the Trump administration.  After peaking in February 2021, shares of Investor's Business Daily's Medical-Biomed/Biotech industry group plummeted more than 64% through April 2025.",
    "url": "https://finnhub.io/api/news?id=e8ea41ebef224f9fda023958cdfd9168fa4c948e91a1d23dd0c75f1ea2d84335",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767877251,
      "headline": "Biotech Stocks' Dark Winter Is Over. What That Means For Investors.",
      "id": 138036589,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The long winter for biotech stocks is over.  Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, and a surprising, if uneasy, alliance with the Trump administration.  After peaking in February 2021, shares of Investor's Business Daily's Medical-Biomed/Biotech industry group plummeted more than 64% through April 2025.",
      "url": "https://finnhub.io/api/news?id=e8ea41ebef224f9fda023958cdfd9168fa4c948e91a1d23dd0c75f1ea2d84335"
    }
  },
  {
    "ts": null,
    "headline": "ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook",
    "summary": "Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target engagement data expected in H1 2026, followed by inclusion of a patient cohortDevelopment Candidates selected for pipeline programs AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3)Strategic collaboration with Eli Lilly achieved $4.5 million in milestones in 2025, contributing to st",
    "url": "https://finnhub.io/api/news?id=1cc44718e6ed9917e83811095962f00aa930de0095a6de985eec153c17747de1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767877200,
      "headline": "ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook",
      "id": 138036591,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target engagement data expected in H1 2026, followed by inclusion of a patient cohortDevelopment Candidates selected for pipeline programs AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3)Strategic collaboration with Eli Lilly achieved $4.5 million in milestones in 2025, contributing to st",
      "url": "https://finnhub.io/api/news?id=1cc44718e6ed9917e83811095962f00aa930de0095a6de985eec153c17747de1"
    }
  },
  {
    "ts": null,
    "headline": "Benchling and Lilly TuneLab Partner to Democratize Access to AI Models for Scientists Everywhere",
    "summary": "Benchling, the platform for scientific progress, today announced a strategic collaboration with Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform created by Eli Lilly and Company (Lilly) to provide access to models trained on decades of Lilly's proprietary research data, representing over $1 billion in research investment. Through this program, Lilly is extending TuneLab's reach to Benchling's customer base of more than 1,300 biotech companies. Scientists will be ab",
    "url": "https://finnhub.io/api/news?id=45dadfde367b4ecd25cea5073d451ea5bdadcd4c78e4accbdc91e9041a872504",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767877200,
      "headline": "Benchling and Lilly TuneLab Partner to Democratize Access to AI Models for Scientists Everywhere",
      "id": 138036590,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Benchling, the platform for scientific progress, today announced a strategic collaboration with Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform created by Eli Lilly and Company (Lilly) to provide access to models trained on decades of Lilly's proprietary research data, representing over $1 billion in research investment. Through this program, Lilly is extending TuneLab's reach to Benchling's customer base of more than 1,300 biotech companies. Scientists will be ab",
      "url": "https://finnhub.io/api/news?id=45dadfde367b4ecd25cea5073d451ea5bdadcd4c78e4accbdc91e9041a872504"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Fall; Lockheed, Defense Giants Bounce On $1.5 Trillion Trump 'Dream Military'",
    "summary": "Futures fell. Lockheed Martin and other defense giants jumped on Trump's proposed $1.5 trillion \"Dream Military\" budget.",
    "url": "https://finnhub.io/api/news?id=8763b2c47caa2bbec9fdd0959ad74eda25374a07a50798511a902d57b05352f5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767874107,
      "headline": "Dow Jones Futures Fall; Lockheed, Defense Giants Bounce On $1.5 Trillion Trump 'Dream Military'",
      "id": 138034901,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Futures fell. Lockheed Martin and other defense giants jumped on Trump's proposed $1.5 trillion \"Dream Military\" budget.",
      "url": "https://finnhub.io/api/news?id=8763b2c47caa2bbec9fdd0959ad74eda25374a07a50798511a902d57b05352f5"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Johnson & Johnson: “I Think It’s a Terrific Entry Point”",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer offered insights on. Cramer highlighted the company’s latest spin-off plans for one of its divisions, as he commented: “The fastest grower, the best opportunity here would not be Eli Lilly, which has moved a great deal and I still like, but Johnson & Johnson. […]",
    "url": "https://finnhub.io/api/news?id=bba4de0690500d2b1c69720b1269471493564386b4cfb4c10b8abffc454c4e8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767876310,
      "headline": "Jim Cramer on Johnson & Johnson: “I Think It’s a Terrific Entry Point”",
      "id": 138036593,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer offered insights on. Cramer highlighted the company’s latest spin-off plans for one of its divisions, as he commented: “The fastest grower, the best opportunity here would not be Eli Lilly, which has moved a great deal and I still like, but Johnson & Johnson. […]",
      "url": "https://finnhub.io/api/news?id=bba4de0690500d2b1c69720b1269471493564386b4cfb4c10b8abffc454c4e8c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn",
    "summary": "The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.",
    "url": "https://finnhub.io/api/news?id=c8322ca0e52990a5874875ddee660d42c037ca7bac4fd73886258a9f42dde9db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767873886,
      "headline": "Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn",
      "id": 138036594,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.",
      "url": "https://finnhub.io/api/news?id=c8322ca0e52990a5874875ddee660d42c037ca7bac4fd73886258a9f42dde9db"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Growth Story Has A Lot To Prove In 2026",
    "summary": "Hims & Hers stock is down 50% from all-time highs amid fading momentum in compounded GLP-1 offerings, while new growth vectors are yet to pay off. Read the latest analysis here.",
    "url": "https://finnhub.io/api/news?id=e42277ecd7529e0a356b8afdc2b28ec5d6366cabd23e564e656a9da698c732b5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767873252,
      "headline": "Hims & Hers Growth Story Has A Lot To Prove In 2026",
      "id": 138037643,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2227430855/image_2227430855.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Hims & Hers stock is down 50% from all-time highs amid fading momentum in compounded GLP-1 offerings, while new growth vectors are yet to pay off. Read the latest analysis here.",
      "url": "https://finnhub.io/api/news?id=e42277ecd7529e0a356b8afdc2b28ec5d6366cabd23e564e656a9da698c732b5"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Fall, But Lockheed, Defense Giants Rebound; Google Trumps Apple",
    "summary": "Futures fell. Lockheed Martin and other defense giants jumped on Trump's proposed $1.5 trillion \"Dream Military\" budget.",
    "url": "https://finnhub.io/api/news?id=720426151bbf311f9f75286ae22dbfa30d70ea15bcc12784d6494adf1fa170e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767872738,
      "headline": "Dow Jones Futures Fall, But Lockheed, Defense Giants Rebound; Google Trumps Apple",
      "id": 138034949,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Futures fell. Lockheed Martin and other defense giants jumped on Trump's proposed $1.5 trillion \"Dream Military\" budget.",
      "url": "https://finnhub.io/api/news?id=720426151bbf311f9f75286ae22dbfa30d70ea15bcc12784d6494adf1fa170e6"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly in Advanced Talks to Buy Ventyx for About $1 Billion",
    "summary": "Sources say Lilly is discussing a $14-a-share cash deal for Ventyx, potentially announced as soon as Wednesday.",
    "url": "https://finnhub.io/api/news?id=bda4986f2af0d20906f5d41344555aa1d45f4cdf2461170a6e00551b25bcafa3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767872734,
      "headline": "Eli Lilly in Advanced Talks to Buy Ventyx for About $1 Billion",
      "id": 138034980,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Sources say Lilly is discussing a $14-a-share cash deal for Ventyx, potentially announced as soon as Wednesday.",
      "url": "https://finnhub.io/api/news?id=bda4986f2af0d20906f5d41344555aa1d45f4cdf2461170a6e00551b25bcafa3"
    }
  },
  {
    "ts": null,
    "headline": "Analysis-Drugmakers brace for Europe pricing fight after Trump's US price-cut deals",
    "summary": "By Michael Erman and Maggie Fick NEW YORK/LONDON, Jan 8 (Reuters) - Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to cut U.S",
    "url": "https://finnhub.io/api/news?id=3caf37cdcc32a90b8ec985e24d96e4a87520ed70855f300994586cff4aee08d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767871799,
      "headline": "Analysis-Drugmakers brace for Europe pricing fight after Trump's US price-cut deals",
      "id": 138034981,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "By Michael Erman and Maggie Fick NEW YORK/LONDON, Jan 8 (Reuters) - Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to cut U.S",
      "url": "https://finnhub.io/api/news?id=3caf37cdcc32a90b8ec985e24d96e4a87520ed70855f300994586cff4aee08d0"
    }
  },
  {
    "ts": null,
    "headline": "Best Growth Stocks to Buy for January 8th",
    "summary": "MU, LLY and SKIL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 8th, 2026.",
    "url": "https://finnhub.io/api/news?id=c1ef335003829997ec34b33b1f75dce16b23ea418b7a64c2ff17b936a9652906",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767865500,
      "headline": "Best Growth Stocks to Buy for January 8th",
      "id": 138034982,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "MU, LLY and SKIL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 8th, 2026.",
      "url": "https://finnhub.io/api/news?id=c1ef335003829997ec34b33b1f75dce16b23ea418b7a64c2ff17b936a9652906"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks In Focus: Assessing The Outlook For 2026",
    "summary": "After a prolonged slump, investors are giving the healthcare sector a second look. TD Asset Management's Jacky He discusses potential drivers for biotech and pharmaceutical stocks in 2026.",
    "url": "https://finnhub.io/api/news?id=3274ac6c8006bb91e5a1e993463154bbb35619d530559a7095996210d5b0fa19",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767850200,
      "headline": "Healthcare Stocks In Focus: Assessing The Outlook For 2026",
      "id": 138034430,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487494602/image_1487494602.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "After a prolonged slump, investors are giving the healthcare sector a second look. TD Asset Management's Jacky He discusses potential drivers for biotech and pharmaceutical stocks in 2026.",
      "url": "https://finnhub.io/api/news?id=3274ac6c8006bb91e5a1e993463154bbb35619d530559a7095996210d5b0fa19"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Fall; Eli Lilly Breaks Out, Google Trumps Apple",
    "summary": "The S&P 500 and Dow reversed from highs Wednesday, while the Nasdaq pared gains. Eli Lilly and Google flashed buy signals.",
    "url": "https://finnhub.io/api/news?id=a01e2f4cdd257ebf547b2360d1b17da27d6ff448b07bf6ddb59034287b84f9b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767844392,
      "headline": "Dow Jones Futures Fall; Eli Lilly Breaks Out, Google Trumps Apple",
      "id": 138032859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The S&P 500 and Dow reversed from highs Wednesday, while the Nasdaq pared gains. Eli Lilly and Google flashed buy signals.",
      "url": "https://finnhub.io/api/news?id=a01e2f4cdd257ebf547b2360d1b17da27d6ff448b07bf6ddb59034287b84f9b4"
    }
  }
]